ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 36644237

A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.

Harrison SA and 13 others. JHEP Rep, 2023. Cited by 92 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. Papers, record 36644237. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36644237

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
PubMed
Journal
JHEP Rep
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
92
iCite
Relative citation ratio, by iCite
6.52
iCite
Revised in PubMed
2023-01-17
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Harrison SAStephen A
2Ruane PJPeter J
3Freilich BBradley
4Neff GGuy
5Patil RRashmee
6Behling CCynthia
7Hu CChen
8Shringarpure RReshma
9de Temple BBrittany
10Fong EErica

1 to 10 of 14Source PubMed

See all 14 authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03976401A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)Derived from the trialYes

Source ClinicalTrials.gov

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References47

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128,130,788Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.Hepatology2017https://conductscience.org/library/papers/28130788PubMed
229,990,488Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.Gastroenterology2018https://conductscience.org/library/papers/29990488PubMed
326,505,821Are Biochemical Markers of Bone Turnover Representative of Bone Histomorphometry in 370 Postmenopausal Women?J Clin Endocrinol Metab2015https://conductscience.org/library/papers/26505821PubMed
423,766,126Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice.Endocrinology2013https://conductscience.org/library/papers/23766126PubMed
532,483,404Fibroblast Growth Factor-21 ameliorates hepatic encephalopathy by activating the STAT3-SOCS3 pathway to inhibit activated hepatic stellate cells.EXCLI J2020https://conductscience.org/library/papers/32483404PubMed
632,027,911Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Gastroenterology2020https://conductscience.org/library/papers/32027911PubMed
718,687,777Fibroblast growth factor 21 corrects obesity in mice.Endocrinology2008https://conductscience.org/library/papers/18687777PubMed
832,147,362Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.J Hepatol2020https://conductscience.org/library/papers/32147362PubMed
933,205,064AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients.Cell Rep Med2020https://conductscience.org/library/papers/33205064PubMed
1029,880,964NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances.Am J Gastroenterol2018https://conductscience.org/library/papers/29880964PubMed

1 to 10 of 47

See all 47 references

Cited by66

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 92 citations.

PMIDTitleJournalYearIn PapersSource
42,883,860Canonical and Non-Canonical Regulators of Lipid Metabolism in the Liver and the "Liver-Other Organs" Axes.Int J Mol Sci2026https://conductscience.org/library/papers/42883860PubMed
42,670,691Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Treatment Strategies and Novel Therapies.Gut Liver2026https://conductscience.org/library/papers/42670691PubMed
42,633,326Advances in FGF/FGFR Signaling: Implications for Disease and Therapy.MedComm (2020)2026https://conductscience.org/library/papers/42633326PubMed
42,627,051Decoding fibroblast activation: Transcriptional networks in hepatic stellate cells and across fibrotic organs (Review).Int J Mol Med2026https://conductscience.org/library/papers/42627051PubMed
42,577,825Pharmacologic management of metabolic and alcohol-associated liver disease.Metab Target Organ Damage2026https://conductscience.org/library/papers/42577825PubMed
42,438,128Drug Development for MASH-Related Compensated Cirrhosis: Past, Present and Future.Liver Int2026https://conductscience.org/library/papers/42438128PubMed
42,325,618Updating the MASH pharmacotherapy landscape: a network meta-analysis incorporating SGLT2 inhibitors and emerging combination therapies.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42325618PubMed
42,255,485Fibroblast Growth Factor 21 Analogues Improve Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis: An Updated Systematic Review and Meta-Analysis.Int J Hepatol2026https://conductscience.org/library/papers/42255485PubMed
42,233,597The Framework of Precision Pharmacotherapy in Metabolic Dysfunction-Associated Steatohepatitis: A Network Meta-Analysis.Clin Pharmacol Ther2026https://conductscience.org/library/papers/42233597PubMed
42,007,332Efficacy and safety of efruxifermin for patients with NASH/MASH: an updated systematic review and meta-analysis.Front Pharmacol2025https://conductscience.org/library/papers/42007332PubMed

1 to 10 of 66

See all 66 cited by

Genes22

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ADIPOQ9,370PubTator's text mininghttps://conductscience.org/library/genes/9370NCBI Gene
ALB213PubTator's text mininghttps://conductscience.org/library/genes/213NCBI Gene
ALPP250PubTator's text mininghttps://conductscience.org/library/genes/250NCBI Gene
APOB338PubTator's text mininghttps://conductscience.org/library/genes/338NCBI Gene
APOC3345PubTator's text mininghttps://conductscience.org/library/genes/345NCBI Gene
BGLAP632PubTator's text mininghttps://conductscience.org/library/genes/632NCBI Gene
CRP1,401PubTator's text mininghttps://conductscience.org/library/genes/1401NCBI Gene
FASTK10,922PubTator's text mininghttps://conductscience.org/library/genes/10922NCBI Gene
FGB2,244PubTator's text mininghttps://conductscience.org/library/genes/2244NCBI Gene
FGF2126,291PubTator's text mininghttps://conductscience.org/library/genes/26291NCBI Gene

1 to 10 of 22

See all 22 genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
EFRUXIFERMINCHEMBL4594389Derived from the trial1https://conductscience.org/library/drugs/CHEMBL4594389

Source ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36644237

GET https://conductscience.org/api/papers/v1/36644237/references?page=2

API referenceFor AI assistants